A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers: Difference between revisions
Rim Halaby (talk | contribs) |
Rim Halaby (talk | contribs) |
||
Line 63: | Line 63: | ||
==Conclusion== | ==Conclusion== | ||
Single and multiple infusions of CSL-112 in healthy subjects rapidly initiates the reverse cholesterol transport, and this is beneficial in rapidly lowering the risk of recurrent cardiovascular events following acute coronary syndromes.<ref name="circ.ahajournals.org">{{Cite web | last = | first = | title = http://circ.ahajournals.org/cgi/content/meeting_abstract/126/21_MeetingAbstracts/A11851 | url = http://circ.ahajournals.org/cgi/content/meeting_abstract/126/21_MeetingAbstracts/A11851 | publisher = | date = | accessdate = 16 September 2013 }}</ref> | Single and multiple infusions of CSL-112 in healthy subjects rapidly initiates the reverse [[cholesterol transport]], and this is beneficial in rapidly lowering the risk of recurrent [[cardiovascular events]] following [[acute coronary syndromes]].<ref name="circ.ahajournals.org">{{Cite web | last = | first = | title = http://circ.ahajournals.org/cgi/content/meeting_abstract/126/21_MeetingAbstracts/A11851 | url = http://circ.ahajournals.org/cgi/content/meeting_abstract/126/21_MeetingAbstracts/A11851 | publisher = | date = | accessdate = 16 September 2013 }}</ref> | ||
==References== | ==References== |
Revision as of 04:15, 19 September 2013
High Density Lipoprotein Microchapters |
Diagnosis |
---|
Treatment |
Clinical Trials |
Case Studies |
A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers On the Web |
American Roentgen Ray Society Images of A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers |
FDA on A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers |
CDC on A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers |
A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers in the news |
Blogs on A Multiple Ascending Dose Study of CSL112 in Healthy Volunteers |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Objective
- To measure the biomarkers of cholesterol movement following a single and multiple infusions of CSL-112 in healthy subjects.
- To evaluate role of CSL-112 in decreasing cholesterol-loaded plaques that contribute to cardiovascular disease.
Timeline
Start Date
June 2010
End Date for Final Data Collection for Primary Outcomes
December 2010
Study Completion Date
January 2011
Methods
- Phase I study
- Adaptive, randomized, placebo-controlled, double-blinded, sponsor-unblinded, multiple ascending dose study
- Patients enrolled: 36 healthy subjects
Inclusion Criteria
- Healthy individual
- Age: 18-55 year old
- Weight ≥ 5 kg
- BMI between 18-42 kg/m2
Exclusion Criteria
- Clinically significant medical condition or disease
- Abnormal lab test result
- History of alcohol or other substance abuse
Study Arms
- Intravenous placebo infusions composed of 0.9% normal saline
- Single escalating intravenous doses of CSL112 composed of reconstituted HDL. There are 3 dosing groups: 4 once-weekly infusions of 3.4 g, 4 once-weekly infusions of 6.8 g, and 8 twice-weekly infusions of 3.4 g.
Biomarkers of cholesterol movement - cholesterol efflux capacity, serum preBeta1-HDL and HDL were measured.
Outcomes
Primary Outcomes
Safety and tolerability defined as rate of clinically associated adverse events that occur within 14 days of CSL112 infusion.
Secondary Outcomes
Evaluation of lipoprotein pharmacokinetics during a time frame of 10 days following CSL112 infusion and measurement of plasma levels of lipoprotein.
Results
- Infusions of CSL-112 caused immediate and profound elevation in all the biomarkers.
- Serum preBeta1-HDL elevation was up to 20-fold.
- Serum preBeta1-HDL and cholesterol efflux capacity peaked after infusion and returned to baseline at 24 hour while there was a 72 hour sustained response for serum HDL following its peak at 24-48 hours after infusion.
- Multiple infusions of CSL112 causes a greater efflux of cholesterol from tissues to HDL when compared with a single infusion.
- No observed changes in the baseline of other lipoproteins.
Conclusion
Single and multiple infusions of CSL-112 in healthy subjects rapidly initiates the reverse cholesterol transport, and this is beneficial in rapidly lowering the risk of recurrent cardiovascular events following acute coronary syndromes.[1]
References
- ↑ "http://circ.ahajournals.org/cgi/content/meeting_abstract/126/21_MeetingAbstracts/A11851". Retrieved 16 September 2013. External link in
|title=
(help)